EA202091885A1 - Формы сокристаллов аналога новобиоцина и пролина - Google Patents

Формы сокристаллов аналога новобиоцина и пролина

Info

Publication number
EA202091885A1
EA202091885A1 EA202091885A EA202091885A EA202091885A1 EA 202091885 A1 EA202091885 A1 EA 202091885A1 EA 202091885 A EA202091885 A EA 202091885A EA 202091885 A EA202091885 A EA 202091885A EA 202091885 A1 EA202091885 A1 EA 202091885A1
Authority
EA
Eurasian Patent Office
Prior art keywords
forms
socrystals
prolin
novobiocin
analogue
Prior art date
Application number
EA202091885A
Other languages
English (en)
Russian (ru)
Inventor
Синь Цзянь
Джон Аллен Уоллинг
Мелани Дж. Бевилл
Кристофер С. Сидеек
Джаред П. Смит
Original Assignee
Реата Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Реата Фармасьютикалс, Инк. filed Critical Реата Фармасьютикалс, Инк.
Publication of EA202091885A1 publication Critical patent/EA202091885A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
EA202091885A 2018-02-07 2019-02-01 Формы сокристаллов аналога новобиоцина и пролина EA202091885A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Publications (1)

Publication Number Publication Date
EA202091885A1 true EA202091885A1 (ru) 2021-01-15

Family

ID=65444361

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091885A EA202091885A1 (ru) 2018-02-07 2019-02-01 Формы сокристаллов аналога новобиоцина и пролина

Country Status (19)

Country Link
US (3) US10717755B2 (cg-RX-API-DMAC10.html)
EP (1) EP3749675B1 (cg-RX-API-DMAC10.html)
JP (3) JP2021512910A (cg-RX-API-DMAC10.html)
KR (2) KR102718111B1 (cg-RX-API-DMAC10.html)
CN (2) CN112020506B (cg-RX-API-DMAC10.html)
AR (1) AR114245A1 (cg-RX-API-DMAC10.html)
AU (3) AU2019217821B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020016205A2 (cg-RX-API-DMAC10.html)
CA (2) CA3090646C (cg-RX-API-DMAC10.html)
CL (2) CL2020002051A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020009761A2 (cg-RX-API-DMAC10.html)
EA (1) EA202091885A1 (cg-RX-API-DMAC10.html)
IL (2) IL315865A (cg-RX-API-DMAC10.html)
MX (2) MX2020008326A (cg-RX-API-DMAC10.html)
MY (1) MY209803A (cg-RX-API-DMAC10.html)
PE (1) PE20211446A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202007530XA (cg-RX-API-DMAC10.html)
TW (3) TWI868593B (cg-RX-API-DMAC10.html)
WO (1) WO2019156907A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016205A2 (pt) 2018-02-07 2020-12-15 Reata Pharmaceuticals, Inc. Formas cocristalinas de prolina e de análogo de novobiocina
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013006651A2 (pt) 2010-09-23 2017-07-18 Nuformix Ltd composição e cocristal de aprepitante l-prolina
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
CN108640910A (zh) * 2011-11-25 2018-10-12 诺弗米克斯技术有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
BR112014019704B1 (pt) * 2012-02-09 2022-05-31 University Of Kansas Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
US9556216B2 (en) * 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CA3289739A1 (en) 2014-06-24 2025-11-29 The University Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
PT3202772T (pt) * 2014-09-30 2020-11-20 Jiangsu Hengrui Medicine Co Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2
BR112020016205A2 (pt) 2018-02-07 2020-12-15 Reata Pharmaceuticals, Inc. Formas cocristalinas de prolina e de análogo de novobiocina

Also Published As

Publication number Publication date
IL276583B1 (en) 2024-11-01
KR20240155354A (ko) 2024-10-28
AU2019217821B2 (en) 2022-09-08
MX2022012856A (es) 2022-11-30
SG11202007530XA (en) 2020-09-29
US11401294B2 (en) 2022-08-02
JP2024001167A (ja) 2024-01-09
AU2022283638B2 (en) 2024-07-25
WO2019156907A1 (en) 2019-08-15
AU2019217821A1 (en) 2020-09-24
US20190241599A1 (en) 2019-08-08
MX2020008326A (es) 2020-09-28
IL276583A (en) 2020-09-30
CL2020002051A1 (es) 2021-02-19
AR114245A1 (es) 2020-08-12
TW202510893A (zh) 2025-03-16
CN112020506B (zh) 2024-10-11
CN118894894A (zh) 2024-11-05
JP2021512910A (ja) 2021-05-20
US10717755B2 (en) 2020-07-21
KR102718111B1 (ko) 2024-10-17
CO2020009761A2 (es) 2020-10-30
TW201945381A (zh) 2019-12-01
EP3749675A1 (en) 2020-12-16
MY209803A (en) 2025-08-05
IL276583B2 (en) 2025-03-01
NZ767558A (en) 2024-11-29
BR112020016205A2 (pt) 2020-12-15
AU2022283638A1 (en) 2023-02-02
US20240043465A1 (en) 2024-02-08
CA3090646C (en) 2024-02-27
PE20211446A1 (es) 2021-08-05
TWI797249B (zh) 2023-04-01
TWI868593B (zh) 2025-01-01
US20200347088A1 (en) 2020-11-05
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CA3226385A1 (en) 2019-08-15
AU2024227646A1 (en) 2024-11-14
CL2022003784A1 (es) 2023-06-09
JP2026012851A (ja) 2026-01-27
CA3090646A1 (en) 2019-08-15
CN112020506A (zh) 2020-12-01
IL315865A (en) 2024-11-01
TWI915111B (zh) 2026-02-11
EP3749675B1 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
NZ629778A (en) C-terminal hsp90 inhibitors
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
ECSP19053616A (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
EA202190547A1 (ru) Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинами
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA201792421A1 (ru) Амидозамещенные производные циклогексана
ATE528005T1 (de) 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
CL2022003784A1 (es) Formas co-cristalinas de un análogo de novobiocina y prolina
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
EA201991898A1 (ru) Двойные ингибиторы magl и faah
EA202091428A1 (ru) Замещенные амиды ii пирролидина
EA202190899A1 (ru) АРИЛСУЛЬФОНИЛПИРРОЛКАРБОКСАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АКТИВАТОРОВ КАЛИЕВЫХ КАНАЛОВ Kv3
EA202192008A1 (ru) Lilrb3-связывающие молекулы и варианты их применения
EA202190452A1 (ru) Ингибиторы cdk8/19
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
EA201692185A1 (ru) Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
EA202090682A1 (ru) Модуляторы кальциевых каналов, активируемых высвобождением кальция, для лечения гематологических и солидных раковых заболеваний
EA200901656A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ ITPKb